The liver cancer diagnostics market in North America is expected to grow from US$ 3,843.93 million in 2021 to US$ 6,666.24 million by 2028. It is estimated to grow at a CAGR of 8.2% from 2021 to 2028.
ย North America Liver Cancer Diagnostics Market The ability to accurately diagnose liver cancer progression is critical for selecting the appropriate treatment option. Further, various companies and organizations have taken enormous initiatives to develop and implement innovative solutions for the early identification of this disease in response to the rising demand. For instance, in March 2020, Roche Holding AG's Elecsys GALAD score received the US Food and Drug Administration's breakthrough device status for the early detection of an advanced form of liver cancer. North America Liver Cancer Diagnostics Market The Swiss drugmaker's calculator combines factors including age, gender, and biomarker results to detect early-stage hepatocellular carcinoma, which is the most common form of liver cancer. Further, Elecsys GALAD score is designed to support clinicians by providing them with a timely and accurate diagnosis of hepatocellular carcinoma.
North America Liver Cancer Diagnostics Market
North America Liver Cancer Diagnostics Market Liver cancer, particularly hepatocellular carcinoma (HCC), is one of the leading causes of cancer-related mortality worldwide. The increasing prevalence of liver disease, particularly due to rising rates of chronic hepatitis B and C infections, alcohol-related liver disease, and non-alcoholic fatty liver disease (NAFLD), has led to an increase in the number of liver cancer cases. In North America, the growing demand for effective and early diagnostic tools to detect liver cancer has fostered the expansion of the liver cancer diagnostics market.This article will examine the factors driving the growth of the North American liver cancer diagnostics market, key diagnostic methods, market challenges, and future prospects in the region.
๐ ๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐
๐๐จ๐ฉ๐ฒ@ https://www.businessmarketinsights.com/sample/BMIRE00025043
North America Liver Cancer Diagnostics Market The research and development (R&D) expenditure in 2021 was US$ 14.65 billion, and in 2020, it was US$ 13.17 billion. The research and development (R&D) expenditure grew by 14% on a core basis in F. Hoffmann-La Roche Ltd., North America Liver Cancer Diagnostics Market mostly driven by late-stage investments in oncology, ophthalmology, and personalized healthcare. In 2021, the R&D investment in the diagnostic division was US$ 1,878.92 million. Similarly, In November 2019, EXACT Sciences Corporation received the Food and Drug Administration's (FDA) breakthrough designation for its blood-based test for early detection of liver cancer.Additionally, in June 2020, National Institutes of Health (NIH) scientists developed blood tests to help improve liver cancer screening, led by researchers at the National Cancer Institute (NCI). In addition, in June 2019, CancerSEEK, a liquid biopsy test, was designed by researchers at Johns Hopkins University. North America Liver Cancer Diagnostics Market The test was designed to diagnose multiple cancers, including stomach, liver, ovarian, and esophageal, at an early stage, facilitating early treatment. Therefore, the increasing R&D investments and development of diagnostic tests for the detection of liver cancer are driving the liver cancer diagnostics market.
With new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the North America Liver cancer diagnostics market at a substantial CAGR during the forecast period.
๐๐ก๐ ๐๐ข๐ฌ๐ญ ๐จ๐ ๐๐จ๐ฆ๐ฉ๐๐ง๐ข๐๐ฌ
Abbott
bioMerieux SA
F. HOFFMANN-LA ROCHE LTD.
Illumina, Inc.
Koninklijke Philips N.V.
QIAGEN
Siemens Healthineers AG
THERMO FISHER SCIENTIFIC INC.
GE Healthcare
Perspectum
๐๐
๐ฎ๐ฅ๐ฅ ๐๐๐ฉ๐จ๐ซ๐ญ ๐๐ข๐ง๐ค @ https://www.businessmarketinsights.com/reports/north-america-liver-cancer-diagnostics-market
Drivers of Market Growth
Several factors are contributing to the expansion of the liver cancer diagnostics market in North America:
1.Rising Incidence of Liver Cancer: North America Liver Cancer Diagnostics Market The number of liver cancer cases in North America has been steadily increasing, driven by the growing incidence of risk factors like chronic hepatitis infections, alcohol abuse, and NAFLD. The Centers for Disease Control and Prevention (CDC) has reported a significant rise in the rates of liver cancer in the United States in recent years, underscoring the urgent need for improved diagnostic tools.
2.Technological Advancements in Diagnostic Tools: North America Liver Cancer Diagnostics Market The development of advanced imaging technologies such as contrast-enhanced ultrasound (CEUS), elastography, and molecular diagnostic tests has made early detection of liver cancer more accurate and accessible. The increasing adoption of non-invasive diagnostic technologies such as liquid biopsy and blood-based biomarker assays has also contributed to the marketโs growth.
3.Government Initiatives and Awareness Campaigns: North America Liver Cancer Diagnostics Market Governments and health organizations are investing in liver cancer awareness and screening programs, aiming to detect liver cancer in its early stages when treatment options are more effective. This has spurred the demand for liver cancer diagnostic services, driving market growth.
4.Improved Healthcare Infrastructure: North America Liver Cancer Diagnostics Market The availability of state-of-the-art healthcare facilities, especially in urban areas across the United States and Canada, has increased the accessibility of diagnostic tests. The growing number of specialized cancer centers is contributing to the rise in diagnostic procedures.
5.Aging Population: North America Liver Cancer Diagnostics Market North America has an aging population, and with age being one of the major risk factors for liver cancer, the incidence of liver cancer is expected to rise. This demographic trend is expected to drive the demand for liver cancer diagnostic services, as older individuals are more likely to develop liver disease and cancer.
Liver Biopsy
A liver biopsy, in which a small sample of liver tissue is removed for examination, is a definitive method for diagnosing liver cancer. However, it is invasive and carries certain risks. It is typically used when imaging and biomarker tests cannot provide conclusive results.
Endoscopic Techniques
In some cases, an endoscope may be used to examine the liver for signs of cancer. This is less common but may be employed when other diagnostic tests are inconclusive.
Market Challenges
Despite the promising growth of the liver cancer diagnostics market in North America, several challenges need to be addressed:
High Costs of Diagnostic Tests: The cost of advanced diagnostic tools, particularly imaging techniques like MRI and CT scans, can be prohibitive for some patients. This may limit access to timely diagnosis for certain populations, especially those without adequate insurance coverage.
False Positives and False Negatives: Diagnostic tests, particularly blood biomarkers like AFP, can sometimes produce false positives or negatives. This can lead to misdiagnosis, unnecessary treatments, or delayed diagnosis, all of which can affect patient outcomes.
Limited Access in Rural Areas: While healthcare facilities in urban centers are well-equipped, rural areas may lack access to specialized liver cancer diagnostic services. This disparity in access to healthcare services can delay diagnosis and treatment for individuals in underserved areas.
Late-Stage Diagnosis: Liver cancer is often diagnosed at advanced stages, when treatment options are limited and survival rates are low. Early-stage liver cancer detection remains a challenge, and further advancements are needed in diagnostic technologies to identify liver cancer at earlier, more treatable stages.
Future Outlook
The future of liver cancer diagnostics in North America looks promising, with several factors driving growth:
Emerging Diagnostic Technologies: Liquid biopsy, a non-invasive blood test, is expected to revolutionize liver cancer diagnostics. This technology allows for the detection of genetic mutations and other biomarkers, offering a more accurate and less invasive alternative to traditional biopsy.
Personalized Medicine: Advances in personalized medicine, which involves tailoring treatment based on individual genetic profiles, will likely increase the need for more sophisticated diagnostic methods, including genetic testing and molecular imaging.
Increased Research and Development: Continued research into liver cancer biomarkers and diagnostic tools will help improve the accuracy of early detection, enabling better treatment outcomes for patients.
Health Policy and Screening Programs: Expanding screening programs and government initiatives for liver cancer detection, especially for high-risk populations, will improve early diagnosis rates and contribute to market growth.
๐๐๐จ๐ฎ๐ญ ๐๐ฌ:
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications.
You can see this-
North America Liquid Biopsy Market- https://postyourarticle.com/north-america-liquid-biopsy-market-identifying-roles-and-objectives-in-coming-years-till-2027/
North America Healthcare Contract Research Organizations (CRO) Services Market-ย https://www.globalpostnews.com/uncategorized/north-america-healthcare-contract-research-organizations-cro-services-market-size-growth-status-analysis-and-forecast-2027/
North America Railway Cyber Security Market- https://www.openpr.com/news/3929498/north-america-coffee-beans-market-regional-share-global-size
North America Acetonitrile Market- https://businessmarketreportsblog.wordpress.com/2025/03/21/north-america-acetonitrile-market-size-growth-status-analysis-and-forecast-2027/